QIMR Berghofer, celebrating its 80th anniversary as a leader in Australian biomedical innovation, is proud to announce its participation in the BIO International Convention 2025, held this week in Boston.
As one of the world’s largest gatherings for the biotechnology sector, BIO2025 brings together over 20,000 industry leaders, researchers, and innovators from more than 70 countries to foster collaboration and accelerate breakthroughs in healthcare and life sciences.
QIMR Berghofer’s delegation, including renowned scientists and business development leaders, is actively engaging with global partners to showcase the Institute’s pioneering research and commercial capabilities.
The Institute’s presence at BIO2025 highlights its commitment to translating cutting-edge discoveries into real-world solutions for cancer, infectious diseases, brain and mental health, and population health.
A key highlight of QIMR Berghofer’s participation is the involvement of Associate Professor Michelle Wykes, Founder and Chief Scientific Officer of Fovero Therapeutics—a spin-out from QIMR Berghofer.
Associate Professor Wykes is presenting on innovative immune pathway discoveries that underpin new therapies for cancer and autoimmune diseases, including Fovero’s lead antibody FT002 and first-in-class immunotherapy FT024, both supported by significant international funding.
There will also be the opportunity to speak to experts from the Institute’s subsidiary Q-Gen Cell Therapeutics, which manufactures advanced cell therapies to treat aggressive cancers and life-threatening viral complications.
This year, as QIMR Berghofer marks eight decades of scientific achievement, the Institute is leveraging BIO2025’s dynamic networking and partnering platform to forge new collaborations, expand its global impact, and attract investment for its research pipeline. The Institute’s contract research and commercialisation teams are available for meetings throughout the convention to explore partnership opportunities in drug development, clinical trials, and advanced therapeutics.
“BIO2025 is a unique opportunity for QIMR Berghofer to connect with international leaders and showcase the breadth of our research and innovation,” said QIMR Berghofer COO Dr Stephen Weller.
“We are excited to share our latest breakthroughs and to build partnerships that will accelerate the translation of our discoveries into life-changing therapies for patients worldwide.”